This results in severe muscle IR and systemic hyperinsulinemia, without obesity, hyperglycemia or hyperlipidemia, thus allowing an assessment of the impact of high insulin levels on cancer, without the confounding effects of other obesity-related factors. The gene discussed is INS; the disease is obesity due to melanocortin 4 receptor deficiency.